Erman Akkus, MD, discusses how oncologists can weigh cross-trial comparisons and reach practical second-line decisions in advanced HCC.
Erman Akkus, MD
Advertisement
Articles by Erman Akkus, MD
Erman Akkus, MD, discusses why second-line treatment in advanced hepatocellular carcinoma remains undefined and how reconstructed patient data can help fill it.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to LYT-200 in R/R High-Risk MDS
2
Japan Approves Subcutaneous Pembrolizumab for All Approved Pembrolizumab Indications
3
NAPISTAR-1-01 Data Support Rapid TUB-040 Development in Biomarker-Unrestricted Ovarian Cancer
4
Making Invisible Cancers Visible: Study Suggests a New Route to Turn ‘Cold’ Tumors ‘Hot’
5